Moderna officially begins Phase 1 trial of experimental HIV vaccine

Moderna – the biotechnology company responsible for one of the COVID-19 vaccines – has announced that the first participant in its phase 1 trial of its experimental in HIV vaccine has been given a dose.

The new vaccine uses the same groundbreaking mRNA technology that both Moderna and Pfizer utilized to create their COVID-19 vaccines.

Related: Untreated HIV may have led to new Omicron variant of Covid-19

AdBridg.cmd.push(function() { AdBridg.display("div-gpt-ad-inarticle1"); });

The technology has proven to be highly effective at producing immune responses and could be a new key to targeting HIV, which has long evaded vaccine technology because it mutates so quickly.

Unlike other vaccines, those made with mRNA technology allow scientists to target multiple variants.

“The mRNA platform makes it easy to develop shots against variants because it just requires an update to the coding sequences in the mRNA that code for the variant,” infectious disease doctor and HIV Medicine Association chair Rajesh Gandhi explained in June.

ANNOUNCEMENT